In 2007, the FDA slapped a warning on Avandia's label after a meta-analysis showed that users faced an increased risk of heart attack and death from cardiovascular problems.
2007年，FDA在经过多因素分析后要求在文迪雅的标签上做出警示，提示患者文迪雅将会增加心脏病发作和心血管疾病死亡的风险。
"Previous meta-analyses suggest that treatment with erythropoiesis-stimulating agents (ESAs) in …CKD increases the risk for death, " write Suetonia C.
“以前的荟萃分析表明，在慢性肾病中使用促进红细胞生成剂制（ESAs）会增加增加死亡风险，”Suetonia C。
应用推荐